Golimumab
Indication
Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy.
Red
Brand:
Simponi®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: